@article {Michel1624, author = {Marc Michel and Cristophe Duvoux and Cristophe Hezode and Daniel Cherqui}, title = {Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still{\textquoteright}s disease.}, volume = {30}, number = {7}, pages = {1624--1625}, year = {2003}, publisher = {The Journal of Rheumatology}, abstract = {Infliximab, a chimeric anti-tumor necrosis factor-alpha monoclonal antibody, has been demonstrated to be efficient and safe in patients with active rheumatoid arthritis and in the management of severe bouts of Crohn{\textquoteright}s disease. However, the safety of infliximab has not been evaluated in patients infected with hepatitis B virus. We report the case of a 28-year-old woman, with a positive hepatitis B virus surface antigen, who developed fulminant hepatitis 2 weeks after receiving a second infliximab infusion for a refractory adult onset Still{\textquoteright}s disease.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/30/7/1624}, eprint = {https://www.jrheum.org/content/30/7/1624.full.pdf}, journal = {The Journal of Rheumatology} }